Hyloris Pharmaceuticals SA Statistics
Hyloris Pharmaceuticals SA (52U) Stock Statistics & Valuation Metrics
Total Valuation
Hyloris Pharmaceuticals SA has a market cap or net worth of EUR 111.44M. The enterprise value is EUR 119.47M.
- Market Cap
- EUR 111.44M
- Enterprise Value
- EUR 119.47M
Share Statistics
Hyloris Pharmaceuticals SA has 28,000,374 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 28,000,374
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
Hyloris Pharmaceuticals SA’s return on equity (ROE) is -0.20 and return on invested capital (ROIC) is -20.40%.
- Return on Equity (ROE)
- -0.20
- Return on Assets (ROA)
- -0.15
- Return on Invested Capital (ROIC)
- -20.40%
- Return on Capital Employed (ROCE)
- -0.21
- Revenue Per Employee
- 185.96K
- Profits Per Employee
- -117.44K
- Employee Count
- 54
- Asset Turnover
- 0.24
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Hyloris Pharmaceuticals SA is -28.85. Hyloris Pharmaceuticals SA’s PEG ratio is -0.87.
- PE Ratio
- -28.85
- PS Ratio
- 17.57
- PB Ratio
- 5.69
- Price to FCF
- -26.20
- Price to Operating Cash Flow
- -27.30
- PEG Ratio
- -0.87
Income Statement
In the last 12 months, Hyloris Pharmaceuticals SA had revenue of 10.04M and earned -6.34M in profits. Earnings per share was -0.22.
- Revenue
- 10.04M
- Gross Profit
- 9.81M
- Operating Income
- -7.13M
- Pretax Income
- -6.34M
- Net Income
- -6.34M
- EBITDA
- -4.85M
- Earnings Per Share (EPS)
- -0.22
Cash Flow
In the last 12 months, operating cash flow was -6.70M and capital expenditures -29,000, giving a free cash flow of -6.73M billion.
- Operating Cash Flow
- -6.70M
- Free Cash Flow
- -6.73M
- Free Cash Flow per Share
- -0.23
Dividends & Yields
Hyloris Pharmaceuticals SA pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -3.82%
- Earnings Yield
- -3.47%
Stock Price Statistics
- Beta
- 0.46
- 52-Week Price Change
- -22.16%
- 50-Day Moving Average
- 4.02
- 200-Day Moving Average
- 4.89
- Relative Strength Index (RSI)
- 54.29
- Average Volume (3m)
- 374
Important Dates
Hyloris Pharmaceuticals SA upcoming earnings date is Mar 17, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Sep 24, 2026
- Next Earnings Date
- Mar 17, 2027
- Ex-Dividend Date
- ―
Financial Position
Hyloris Pharmaceuticals SA as a current ratio of 4.15, with Debt / Equity ratio of 5.65%
- Current Ratio
- 4.15
- Quick Ratio
- 4.15
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 4.49
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Hyloris Pharmaceuticals SA has paid -81.00K in taxes.
- Income Tax
- -81.00K
- Effective Tax Rate
- 0.01
Enterprise Valuation
Hyloris Pharmaceuticals SA EV to EBITDA ratio is -31.89, with an EV/FCF ratio of -22.97.
- EV to Sales
- 15.40
- EV to EBITDA
- -31.89
- EV to Free Cash Flow
- -22.97
- EV to Operating Cash Flow
- -23.07
Balance Sheet
Hyloris Pharmaceuticals SA has EUR 24.15M in cash and marketable securities with EUR 1.81M in debt, giving a net cash position of EUR 22.34M billion.
- Cash & Marketable Securities
- EUR 24.15M
- Total Debt
- EUR 1.81M
- Net Cash
- EUR 22.34M
- Net Cash Per Share
- EUR 0.80
- Tangible Book Value Per Share
- EUR 0.97
Margins
Gross margin is 97.74%, with operating margin of -71.00%, and net profit margin of -63.15%.
- Gross Margin
- 97.74%
- Operating Margin
- -71.00%
- Pretax Margin
- -63.15%
- Net Profit Margin
- -63.15%
- EBITDA Margin
- -48.28%
- EBIT Margin
- -60.52%
Analyst Forecast
The average price target for Hyloris Pharmaceuticals SA is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 21.33%
- EPS Growth Forecast
- 27.42%
